semaglutide phase 1 Five Unexpected New Uses for GLP-1 Receptor Agonists Novo Nordisk's semaglutide shows promise

Nine patients died during the study (three in the semaglutide group and six in the placebo group), with no evident clustering of cause of death

The PlexusDx Precision Peptide Genetic Test identifies your genetic variants in key pathwaysincluding GLP1R rs6923761, GIPR rs1800437, and MC4R rs17782313that influence your sensitivity to semaglutide and your energy metabolism

What education should you provide to a client who was prescribed amoxicillin-clavulanate

Apr 07, 2026, 08:00 ET Wegovy HD available through 70,000+ US pharmacies, NovoCare Pharmacy, select telehealth providers, and more STEP UP trial data showed average weight loss of ~21% with Wegovy HD at 72 weeks in adults with obesity if all patients stayed on treatment * and ~19% regardless of whether patients stayed on treatment **1 Wegovy HD further expands the offerings for patients within the Wegovy label, inclusive of multiple formulations, including Wegovy pill, and indications not available with other GLP-1 weight loss medicines PLAINSBORO, N.J., April 7, 2026 /PRNewswire/ -- Wegovy HD (semaglutide) injection 7.2 mg is available now nationwide, delivering the highest weight loss of any Wegovy injection to date